Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 442 across all filing types
Latest filing 2025-10-06 Major Shareholding Noti…
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings', which is the regulatory standard in the UK for disclosing changes in significant share ownership. It explicitly details the acquisition or disposal of voting rights by Lanstead Capital Investors LP in Immupharma PLC, crossing a threshold. This fits the definition of a Major Shareholding Notification (MRQ).
2025-10-06 English
Exercise of Warrants
Share Issue/Capital Change Classification · 1% confidence The document is an RNS announcement from ImmuPharma PLC regarding the 'Exercise of Options' and the subsequent issuance of new ordinary shares. It details the number of shares issued, the consideration received, and the impact on the total issued share capital. This falls under the category of share issuance and capital changes, which is specifically defined as 'Share Issue/Capital Change' (SHA).
2025-09-17 English
Exercise of Warrants
Share Issue/Capital Change Classification · 1% confidence The document is an RNS announcement from ImmuPharma PLC regarding the exercise of warrants and the subsequent issuance of new ordinary shares. It details the number of shares issued, the consideration received, and the updated total voting rights for the company. This falls under the category of share issuance and capital changes.
2025-09-11 English
Appointments of CSO and Head of R&D
Board/Management Information Classification · 1% confidence The document is an official announcement from ImmuPharma PLC regarding the appointment of a new Chief Scientific Officer and Head of R&D. This falls directly under the category of board or management changes. The document is short, distributed via RNS, and clearly focuses on personnel updates rather than financial reports or other specific categories.
2025-09-01 English
ImmuPharma Files New Patent Application for P140:
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement issued via the London Stock Exchange's RNS (Regulatory News Service). It details a specific corporate development—the filing of a new patent application for the company's lead asset, P140. Since this is a general regulatory announcement regarding company operations and intellectual property that does not fit into more specific categories like financial reports, dividends, or board changes, it is classified as a Regulatory Filing (RNS).
2025-09-01 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by Immupharma PLC. It explicitly details a change in shareholding by Lanstead Capital Investors LP, crossing a reporting threshold. This document type is specifically defined as a 'Major Shareholding Notification' (MRQ) in the provided taxonomy.
2025-08-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.